Polgenix, Inc. is developing an imaging instrument, the "2-photon ophthalmoscope", or "2PO", with the capability for non-invasive, repetitive and high-resolution imaging of biochemical processes within human retina. This device will allow early detection of age- and disease- related changes in the eye, long before pathological manifestations of retinal disease become discernable by existing methods. Such real-time retinal imaging will also be critical for evaluation of various therapies for retinal pathology. Thus, patients susceptible to retinal disease could be diagnosed with 2PO and treated well before vision loss occurs. Once developed, the instrument will be used initially for ophthalmic drug screening and establishing objective biomarkers for retinal disease in animal models. Then it will be employed for clinical trials and ultimately for monitoring retinal health and the impact of therapy in patients. Early application of the device toward the development of effective ophthalmic therapies and clinical diagnosis will be leveraged through collaboration with experts in biochemical processes in the eye and high-resolution adaptive optics ophthalmic imaging from Case Western Reserve University and the University of Rochester, respectively.

Public Health Relevance

We seek to develop a novel instrument for noninvasive imaging of the back of the eye with sub-cellular resolution. The instrument will visualize and quantify the age or disease related changes in the biochemical processes within human retina. Our goal is to further understanding of the biochemistry of vision and to enable rapid evaluation of the impact of therapeutic interventions aimed at retinal diseases at the earliest stages, before retina is damaged and vision is irreparably diminished.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
9R44AG043645-02
Application #
8250920
Study Section
Special Emphasis Panel (ZRG1-ETTN-E (12))
Program Officer
Chen, Wen G
Project Start
2012-08-15
Project End
2015-07-31
Budget Start
2012-08-15
Budget End
2013-07-31
Support Year
2
Fiscal Year
2012
Total Cost
$638,403
Indirect Cost
Name
Polgenix, Inc.
Department
Type
DUNS #
785024089
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Sharma, Robin; Schwarz, Christina; Williams, David R et al. (2016) In Vivo Two-Photon Fluorescence Kinetics of Primate Rods and Cones. Invest Ophthalmol Vis Sci 57:647-57
Sharma, Robin; Williams, David R; Palczewska, Grazyna et al. (2016) Two-Photon Autofluorescence Imaging Reveals Cellular Structures Throughout the Retina of the Living Primate Eye. Invest Ophthalmol Vis Sci 57:632-46
Zhang, Jianye; Kiser, Philip D; Badiee, Mohsen et al. (2015) Molecular pharmacodynamics of emixustat in protection against retinal degeneration. J Clin Invest 125:2781-94
Zhang, Ning; Tsybovsky, Yaroslav; Kolesnikov, Alexander V et al. (2015) Protein misfolding and the pathogenesis of ABCA4-associated retinal degenerations. Hum Mol Genet 24:3220-37
Maeda, Akiko; Palczewska, Grazyna; Golczak, Marcin et al. (2014) Two-photon microscopy reveals early rod photoreceptor cell damage in light-exposed mutant mice. Proc Natl Acad Sci U S A 111:E1428-37
Palczewska, Grazyna; Dong, Zhiqian; Golczak, Marcin et al. (2014) Noninvasive two-photon microscopy imaging of mouse retina and retinal pigment epithelium through the pupil of the eye. Nat Med 20:785-9
Palczewska, Grazyna; Vinberg, Frans; Stremplewski, Patrycjusz et al. (2014) Human infrared vision is triggered by two-photon chromophore isomerization. Proc Natl Acad Sci U S A 111:E5445-54
Chen, Yu; Palczewska, Grazyna; Mustafi, Debarshi et al. (2013) Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration. J Clin Invest 123:5119-34
Sharma, Robin; Yin, Lu; Geng, Ying et al. (2013) In vivo two-photon imaging of the mouse retina. Biomed Opt Express 4:1285-93
Maeda, Tadao; Lee, Mee Jee; Palczewska, Grazyna et al. (2013) Retinal pigmented epithelial cells obtained from human induced pluripotent stem cells possess functional visual cycle enzymes in vitro and in vivo. J Biol Chem 288:34484-93